Pharvaris (NASDAQ:PHVS - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06, Zacks reports.
Pharvaris Trading Up 0.8 %
Shares of PHVS traded up $0.10 during trading hours on Friday, reaching $12.00. The company had a trading volume of 56,660 shares, compared to its average volume of 71,419. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50. The firm has a 50 day simple moving average of $15.55 and a 200-day simple moving average of $18.36. The company has a market capitalization of $627.48 million, a price-to-earnings ratio of -4.29 and a beta of -2.84.
Analyst Ratings Changes
Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Report on PHVS
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
